Abstract
The challenge of translational medicine is to translate very complex scientific data into the clinical setting so that medical management can be better guided towards the ultimate goal of better patient outcome. Physicians now have the opportunity to use specific biomarkers to personalize therapeutic options in various settings. Recent research has demonstrated that presence of Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation may directly influence medical decisions in patients with colon and lung cancer. Use of KRAS oncogene as a selection marker for specific treatment is a good example of individualized medicine approach to cancer treatment.
MeSH terms
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Bevacizumab
-
Carcinoma, Non-Small-Cell Lung / genetics
-
Carcinoma, Non-Small-Cell Lung / mortality
-
Colonic Neoplasms / drug therapy
-
Colonic Neoplasms / genetics
-
ErbB Receptors / antagonists & inhibitors
-
Erlotinib Hydrochloride
-
Humans
-
Lung Neoplasms / genetics
-
Lung Neoplasms / mortality
-
Mutation*
-
Precision Medicine
-
Prognosis
-
Proto-Oncogene Proteins / genetics*
-
Proto-Oncogene Proteins p21(ras)
-
Quinazolines / therapeutic use
-
ras Proteins / genetics*
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
KRAS protein, human
-
Proto-Oncogene Proteins
-
Quinazolines
-
Bevacizumab
-
Erlotinib Hydrochloride
-
ErbB Receptors
-
Proto-Oncogene Proteins p21(ras)
-
ras Proteins